Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Oragenics (NYSE:OGEN) in a report released on Wednesday. The firm issued a sell rating on the stock.

Oragenics Trading Down 0.7 %

OGEN stock opened at $0.29 on Wednesday. The company has a market cap of $3.48 million, a price-to-earnings ratio of -0.04 and a beta of 0.85. Oragenics has a 12 month low of $0.25 and a 12 month high of $3.43. The firm has a 50-day moving average of $0.30 and a two-hundred day moving average of $0.39.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.